Copyright
©The Author(s) 2020.
World J Gastrointest Surg. Feb 27, 2020; 12(2): 34-44
Published online Feb 27, 2020. doi: 10.4240/wjgs.v12.i2.34
Published online Feb 27, 2020. doi: 10.4240/wjgs.v12.i2.34
Table 1 Statistical analysis of prognostic factors for disease-free survival
Demographic, clinical and pathological factors | Disease-free survival [median (range) mo] | Uni-variate analysis (P value) | Multi-variate analysis (P value) | Risk ratio (Confidence interval) |
Age | 0.637 | |||
< 65 yr (n = 244) | 18 (3-165) | |||
≥ 65 yr (n = 342) | 18 (3-160) | |||
Gender | 0.588 | |||
Male (n = 389) | 18 (3-165) | |||
Female (n = 197) | 20 (3-153) | |||
Presentation | < 0.001 | 0.003 | 0.684 (0.533-0.877) | |
Synchronous (n = 225) | 15 (3-165) | |||
Metachronous (n = 361) | 20 (3-160) | |||
Neutrophil-to-lymphocyte ratio | 18 (3-165) | 0.272 | ||
< 5 (n = 490) | 21 (3-153) | |||
≥ 5 (n = 96) | ||||
Platelet-to-lymphocyte ratio | 0.114 | |||
< 150 (n = 287) | 17 (3-165) | |||
≥ 150 (n = 299) | 20 (3-156) | |||
Neo-adjuvant chemotherapy | < 0.001 | 0.099 | 0.789 (0.596-1.046) | |
Yes (n = 135) | 13 (3-165) | |||
No (n = 451) | 20 (3-160) | |||
Statin therapy | 0.340 | |||
Yes (n = 181) | 17 (3-160) | |||
No (n = 405) | 19 (3-165) | |||
Deprivation index | 0.083 | |||
1 (n = 101) | 13 (3-131) | |||
2 (n = 120) | 18 (3-159) | |||
3 (n = 115) | 18 (3-147) | |||
4 (n = 142) | 20 (3-123) | |||
5 (n = 108) | 21 (3-165) | |||
Resection < hemi-hepatectomy (n = 368) | 20 (3-165) | 0.015 | 0.369 | 1.124 (0.871-1.449) |
≥ hemi-hepatectomy (n = 218) | 18 (3-160) | |||
Largest tumour size | 0.007 | 0.009 | 1.407 (1.087-1.820) | |
< 5 cm (n = 406) | 20 (3-156) | |||
≥ 5 cm (n = 180) | 16 (3-165) | |||
Number of metastases | < 0.001 | 0.001 | 1.552 (1.204-2.002) | |
Solitary (n = 294) | 22 (3-165) | |||
Multiple (n = 292) | 14 (3-153) | |||
Steatosis | 0.003 | 0.003 | 1.285 (1.086-1.520) | |
None (n = 426) | 18 (3-165) | |||
Mild (n = 97) | 20 (3-153) | |||
Moderate – Severe (n = 63) | 12 (3-144) | |||
Lymphatic invasion | 0.002 | 0.101 | 0.747 (0.527-1.059) | |
Positive (n = 67) | 15 (3-160) | |||
Negative (n = 519) | 20 (3-165) | |||
Vascular invasion | 0.059 | |||
Positive (n = 264) | 16 (3-159) | |||
Negative (n = 322) | 20 (3-165) | |||
Peri-neural invasion | < 0.001 | 0.005 | 0.522 (0.333-0.821) | |
Positive (n = 38) | 12 (3-101) | |||
Negative (n = 548) | 20 (3-165) | |||
Biliary invasion | 0.158 | |||
Positive (n = 181) | 18 (3-159) | |||
Negative (n = 405) | 20 (3-165) | |||
Resection margin (R0) | 0.004 | 0.012 | 1.399 (1.075-1.821) | |
R0 (n = 427) | 19 (3-165) | |||
R1 (n = 159) | 19 (3-156) |
Table 2 Statistical analysis of prognostic factors for overall survival
Demographic, clinical and pathological factors | Overall Survival [median (range) mo] | Uni-variate analysis | Multi-variate analysis | Risk ratio (Confidence interval) |
Age | 0.373 | |||
< 65 yr (n = 244) | 39 (3-165) | |||
≥ 65 yr (n = 342) | 35 (3-160) | |||
Gender | 0.236 | |||
Male (n = 389) | 35 (3-165) | |||
Female (n = 197) | 38 (3-160) | |||
Presentation | 0.189 | |||
Synchronous (n = 225) | 46 (4-165) | |||
Metachronous (n = 361) | 31 (3-160) | |||
Neutrophil-to-lymphocyte ratio | 36 (3-165) | 0.219 | ||
< 5 (n = 490) | 41 (4-153) | |||
≥ 5 (n = 96) | ||||
Platelet-to-lymphocyte ratio | 0.902 | |||
< 150 (n = 287) | 34 (5-165) 41 (3-156) | |||
≥ 150 (n = 299) | ||||
Neo-adjuvant chemotherapy | 37 (4-165) | 0.002 | 0.014 | 0.710 (0.541-0.933) |
Yes (n = 135) | 37 (3-160) | |||
No (n = 451) | ||||
Statin therapy | 0.459 | |||
Yes (n = 181) | 34 (3-160) | |||
No (n = 405) | 38 (3-165) | |||
Deprivation index | 0.324 | |||
1 (n = 101) | 31 (4-152) | |||
2 (n = 120) | 38 (3-160) | |||
3 (n = 115) | 31 (5-147) | |||
4 (n = 142) | 41 (4-159) | |||
5 (n = 108) | 36 (4-165) | |||
Less than hemi-hepatectomy (n = 368) | 38 (3-165) | 0.002 | 0.004 | 1.441 (1.125-1.845) |
Hemi-hepatectomy or more (n = 218) | 36 (3-160) | |||
Largest tumour size | 0.079 | |||
< 5 cm (n = 406) | 38 (3-159) | |||
≥ 5 cm (n = 180) | 33 (3-165) | |||
Number of metastases | 0.015 | 0.216 | 1.171 (0.912-1.504) | |
Solitary (n = 294) | 40 (3-165) | |||
Multiple (n = 292) | 34 (4-159) | |||
Steatosis | 0.512 | |||
None (n = 426) | 32 (3-165) | |||
Mild (n = 97) | 59 (5-154) | |||
Moderate – severe (n = 63) | 67 (7-159) | |||
Lymphatic invasion | 0.440 | |||
Positive (n = 67) | 56 (3-160) | |||
Negative (n = 519) | 35 (3-165) | |||
Vascular invasion | 0.130 | |||
Positive (n = 264) | 34(3-160) | |||
Negative (n = 322) | 40 (4-165) | |||
Peri-neural invasion | < 0.001 | 0.002 | 0.521 (0.342-0.795) | |
Positive (n = 38) | 27 (3-101) | |||
Negative (n = 548) | 38 (3-165) | |||
Biliary invasion | 0.530 | |||
Positive (n = 181) | 37 (3-160) | |||
Negative (n = 405) | 37 (4-165) | |||
Resection margin (R0) | < 0.001 | 0.004 | 1.462 (1.130-1.891) | |
R0 (n = 427) | 39 (3-165) | |||
R1 (n = 159) | 34 (4-160) |
Table 3 Effect of statins on patient and tumour variables
Demographic, clinical and pathological factors | Statin therapy use (n = 181) | No statin therapy use (n = 408) | P value |
Age > 65 yr | 106 | 236 | 0.947 |
Male gender | 119 | 270 | 0.827 |
Synchronous presentation | 67 | 158 | 0.646 |
Neutrophil-to-lymphocyte ratio ≥ 5 | 22 | 74 | 0.065 |
Platelet-to-lymphocyte ratio ≥ 150 | 88 | 211 | 0.436 |
Neo-adjuvant chemotherapy | 38 | 87 | 0.894 |
Hemi-hepatectomy or more | 61 | 157 | 0.241 |
Largest tumour size ≥ 5 cm | 53 | 127 | 0.615 |
Solitary hepatic metastases | 91 | 203 | 0.973 |
Steatosis - None | 127 | 299 | 0.634 |
Lymphatic invasion | 16 | 50 | 0.215 |
Perineural invasion | 13 | 20 | 0.276 |
Vascular invasion | 88 | 176 | 0.246 |
Biliary invasion | 62 | 119 | 0.238 |
Resection margin R0 | 133 | 294 | 0.823 |
- Citation: Alabraba E, Ibrahim H, Olaru A, Cameron I, Gomez D, Group NHS. Retrospective cohort study of statin therapy effect on resected colorectal liver metastases. World J Gastrointest Surg 2020; 12(2): 34-44
- URL: https://www.wjgnet.com/1948-9366/full/v12/i2/34.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v12.i2.34